Figure 1

The Canadian Association of Gastroenterology clinical practice guideline provides an evidence-based framework for managing irritable bowel syndrome, covering diagnosis, dietary modifications, pharmacological treatments, and psychological interventions.

Figure 2

Diagnostic criteria for IBS rely on symptom-based assessment using Rome IV criteria, with limited use of diagnostic tests. Serological screening for celiac disease is recommended as part of the initial evaluation.

Figure 3

Evidence evaluation for probiotic therapies in IBS suggests overall benefit, particularly with combination probiotic preparations. Strain-specific recommendations remain difficult due to heterogeneity in study designs and products evaluated.

Figure 4

Dietary interventions for IBS include the low-FODMAP diet, which has demonstrated efficacy in reducing bloating, abdominal pain, and altered bowel habits. A dietitian-guided three-phase approach (restriction, reintroduction, personalization) is recommended.

Figure 6

Antispasmodic agents including peppermint oil, pinaverium, and trimebutine receive conditional recommendations for IBS symptom management. Evidence quality varies across specific agents.

Figure 7

An algorithmic approach to IBS management stratifies treatment by predominant bowel habit (IBS-C, IBS-D, IBS-M) and symptom severity. First-line interventions include dietary modification and fiber supplementation.